Axsome Therapeutics Inc. Common Stock (AXSM)

About AXSM

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

1,346

Website

www.axsome.com/

Fundamentals

1-day range

$199$205.7

Market cap

$10.86B

P/E (trailing)

—

P/E (forward)

39.54

EPS (trailing)

$-3.76

Dividend yield

—

Beta

0.85

Avg. volume

862.0K

Forecasts

21 analyst ratings

Axsome Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• AXSM

  Axsome Therapeutics Inc. Common Stock

  $199.01

  ▼ 3.52%
  Market cap $10.86BP/E —
  $112.9$260.19
• ABVX

  Abivax SA American Depositary Shares

  $113.41

  ▼ 0.78%
  Market cap $10.74BP/E —
  $60.45$139
• MDGL

  Madrigal Pharmaceuticals Inc. Common Stock

  $534.12

  ▼ 1.76%
  Market cap $11.14BP/E —
  $393.61$615
• SMMT

  Summit Therapeutics Inc. Common Stock

  $13.71

  ▼ 4.33%
  Market cap $10.41BP/E —
  $12.07$29.23
• CYTK

  Cytokinetics Incorporated Common Stock

  $72.17

  ▼ 7.36%
  Market cap $9.51BP/E —
  $35.22$88.31
• ELAN

  Elanco Animal Health Incorporated Common Stock

  $24.12

  ▼ 1.51%
  Market cap $12.85BP/E —
  $17.11$27.98
• SYRE

  Spyre Therapeutics Inc. Common Stock

  $90.4

  ▼ 3.43%
  Market cap $8.35BP/E —
  $14.51$110.18

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Acadia Pharmaceuticals: Another Bite At The Alzheimer's Apple
  SeekingAlpha · 8/24/2026
• Here’s How Much You Would Have Made Owning Axsome Therapeutics Stock In The Last 5 Years
  benzinga · 8/17/2026
• Here’s How Much You Would Have Made Owning Axsome Therapeutics Stock In The Last 5 Years
  Benzinga · 8/17/2026
• What Moved Markets This Week
  SeekingAlpha · 8/15/2026
• If You Invested $100 In Axsome Therapeutics Stock 10 Years Ago, You Would Have This Much Today
  Benzinga · 8/13/2026
• Mizuho Maintains Outperform on Axsome Therapeutics, Raises Price Target to $316
  Benzinga · 8/12/2026
• Axsome Therapeutics Q2 Earnings Review: I Just Can't See The Value Proposition
  SeekingAlpha · 8/11/2026
• Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Raises Price Target to $251
  Benzinga · 8/11/2026
• RBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $297
  Benzinga · 8/11/2026

• Herriot Tabuteau · August 6, 2026 · Option Exercise

  4.7K @ $4.95
• Herriot Tabuteau · August 6, 2026 · Sale

  4.7K @ $213.95
• Herriot Tabuteau · August 5, 2026 · Option Exercise

  45.0K @ $4.95
• Herriot Tabuteau · August 5, 2026 · Sale

  45.0K @ $212.01
• Herriot Tabuteau · July 1, 2026 · Option Exercise

  49.7K @ $4.95
• Herriot Tabuteau · July 1, 2026 · Sale

  49.7K @ $240.25
• Roger Jeffs · June 11, 2026 · Sale

  286 @ $249.12
• Roger Jeffs · June 10, 2026 · Sale

  286 @ $246.18
• Mark Coleman · June 10, 2026 · Sale

  643 @ $249
• Susan Mahony · June 10, 2026 · Sale

  300 @ $246.18
• Susan Mahony · June 9, 2026 · Sale

  300 @ $237.21
• Nick Pizzie · June 9, 2026 · Option Exercise

  33.0K @ $3.5
• Nick Pizzie · June 9, 2026 · Sale

  33.0K @ $240.09
• Herriot Tabuteau · June 9, 2026 · Option Exercise

  49.7K @ $4.95
• Herriot Tabuteau · June 9, 2026 · Sale

  49.7K @ $241.01

Institutional Ownership

March 31, 2026

Total shares held

36.55M

Total value held

$5.90B

Institutional holders

403